JP2015523382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523382A5 JP2015523382A5 JP2015521784A JP2015521784A JP2015523382A5 JP 2015523382 A5 JP2015523382 A5 JP 2015523382A5 JP 2015521784 A JP2015521784 A JP 2015521784A JP 2015521784 A JP2015521784 A JP 2015521784A JP 2015523382 A5 JP2015523382 A5 JP 2015523382A5
- Authority
- JP
- Japan
- Prior art keywords
- metformin
- compound according
- pharmaceutical composition
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 13
- 229960003105 metformin Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical class CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 150000003839 salts Chemical group 0.000 claims 2
- SARHCLAXCDURCW-RSDXMDNYSA-N 3-(diaminomethylidene)-1,1-dimethylguanidine;(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoic acid Chemical compound CN(C)C(=[NH2+])NC(N)=N.CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O SARHCLAXCDURCW-RSDXMDNYSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940000640 docosahexaenoate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims 1
- 229960004329 metformin hydrochloride Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- CGSRZHIDDCTNOE-PPMKJDBRSA-N CCC(C)C(NC(C1)[C@@H]1C(N)N(C)C)=N Chemical compound CCC(C)C(NC(C1)[C@@H]1C(N)N(C)C)=N CGSRZHIDDCTNOE-PPMKJDBRSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261669763P | 2012-07-10 | 2012-07-10 | |
| US61/669,763 | 2012-07-10 | ||
| US201261670376P | 2012-07-11 | 2012-07-11 | |
| US201261670368P | 2012-07-11 | 2012-07-11 | |
| US61/670,368 | 2012-07-11 | ||
| US61/670,376 | 2012-07-11 | ||
| US13/841,970 | 2013-03-15 | ||
| US13/841,970 US8765811B2 (en) | 2012-07-10 | 2013-03-15 | Tri-salt form of metformin |
| PCT/US2013/049984 WO2014011814A1 (en) | 2012-07-10 | 2013-07-10 | Tri-salt form of metformin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015523382A JP2015523382A (ja) | 2015-08-13 |
| JP2015523382A5 true JP2015523382A5 (https=) | 2016-08-18 |
Family
ID=49916541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521784A Pending JP2015523382A (ja) | 2012-07-10 | 2013-07-10 | メトホルミンの三塩形態 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2872483A4 (https=) |
| JP (1) | JP2015523382A (https=) |
| KR (1) | KR20150036235A (https=) |
| CN (1) | CN104684889A (https=) |
| AU (1) | AU2013290168A1 (https=) |
| BR (1) | BR112015000368A2 (https=) |
| CA (1) | CA2878819A1 (https=) |
| IL (1) | IL236613A0 (https=) |
| IN (1) | IN2015KN00076A (https=) |
| MX (1) | MX2015000408A (https=) |
| WO (1) | WO2014011814A1 (https=) |
| ZA (1) | ZA201500274B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853259B2 (en) * | 2013-02-07 | 2014-10-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
| WO2015171516A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| CA2951923A1 (en) * | 2014-06-18 | 2015-12-23 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of active agents |
| US20170119841A1 (en) * | 2015-11-04 | 2017-05-04 | Thetis Pharmaceuticals Llc | Amino acid salts of unsaturated fatty acids |
| ES2827796T3 (es) | 2016-06-03 | 2021-05-24 | Thetis Pharmaceuticals Llc | Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación |
| US10471963B2 (en) | 2017-04-07 | 2019-11-12 | TuSimple | System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle |
| US10737695B2 (en) | 2017-07-01 | 2020-08-11 | Tusimple, Inc. | System and method for adaptive cruise control for low speed following |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
| CN116999398A (zh) * | 2022-06-30 | 2023-11-07 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE261935T1 (de) * | 1997-12-08 | 2004-04-15 | Bristol Myers Squibb Co | Neue metformin salze und verfahren |
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| AU2001213150A1 (en) * | 2000-08-03 | 2002-02-18 | Olga Evgenievna Kolesova | Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
| JP2006520335A (ja) * | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
| EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
| CN101855204B (zh) * | 2007-09-21 | 2013-09-11 | 韩兀生物制药株式会社 | N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物 |
| DK2229158T3 (en) * | 2007-12-20 | 2016-12-12 | Fertin Pharma As | Compressed chewing gum tablet |
| JPWO2009151116A1 (ja) * | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| NZ624963A (en) * | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| EA201370099A1 (ru) * | 2010-10-19 | 2013-11-29 | Элселикс Терапьютикс, Инк. | Терапия на основе лигандов хемосенсорных рецепторов |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| US8853259B2 (en) * | 2013-02-07 | 2014-10-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
-
2013
- 2013-07-10 EP EP13817534.4A patent/EP2872483A4/en not_active Withdrawn
- 2013-07-10 CA CA2878819A patent/CA2878819A1/en not_active Abandoned
- 2013-07-10 MX MX2015000408A patent/MX2015000408A/es unknown
- 2013-07-10 WO PCT/US2013/049984 patent/WO2014011814A1/en not_active Ceased
- 2013-07-10 JP JP2015521784A patent/JP2015523382A/ja active Pending
- 2013-07-10 IN IN76KON2015 patent/IN2015KN00076A/en unknown
- 2013-07-10 BR BR112015000368A patent/BR112015000368A2/pt not_active IP Right Cessation
- 2013-07-10 KR KR20157002264A patent/KR20150036235A/ko not_active Withdrawn
- 2013-07-10 CN CN201380046842.4A patent/CN104684889A/zh active Pending
- 2013-07-10 AU AU2013290168A patent/AU2013290168A1/en not_active Abandoned
-
2015
- 2015-01-11 IL IL236613A patent/IL236613A0/en unknown
- 2015-01-14 ZA ZA2015/00274A patent/ZA201500274B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523382A5 (https=) | ||
| JP2014512333A5 (https=) | ||
| JP6356876B2 (ja) | 抗ウイルス化合物の合成 | |
| JP2022043078A5 (https=) | ||
| JP2013032389A5 (https=) | ||
| JP2019048806A5 (https=) | ||
| JP2010500343A5 (https=) | ||
| JP2012092103A5 (https=) | ||
| JP2015535839A5 (https=) | ||
| JP2017536369A5 (https=) | ||
| JP2014506907A5 (https=) | ||
| AR047972A1 (es) | Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas. | |
| JP2012513416A5 (https=) | ||
| JP2011088926A5 (https=) | ||
| JP2008533007A5 (https=) | ||
| JP2017538689A5 (https=) | ||
| JP2015508092A5 (https=) | ||
| JP2011523952A5 (https=) | ||
| RU2017132330A (ru) | Соли производного хиназолина и способ их получения | |
| JP2016510768A5 (https=) | ||
| JP2016512198A5 (https=) | ||
| JP2006151999A5 (https=) | ||
| JP2013537240A5 (https=) | ||
| JP2015516419A5 (https=) | ||
| TW200916454A (en) | Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |